Comparison of clinicopathological data between patients with LN in severe and non-severe group
| Severe (n=75) | Non-severe (n=10) | P value | |
| Gender (male/female) | 62/75 | 10/0 | 0.348 |
| Age (years) | 31 (25–40) | 28 (25–38) | 0.623 |
| Proteinuria amount (g/24 hours) | 3.98 (2.08–5.86) | 1.64 (0.36–2.44) | <0.001 |
| Serum creatinine (μmol/L) | 98 (70–133) | 59 (54–72) | 0.010 |
| C3 (mg/mL) (mean±SD) | 0.41±0.20 | 0.51±0.18 | 0.145 |
| Number of positive ANA (%) | 72 (96.0) | 10 (100) | 0.520 |
| Number of positive anti-dsDNA antibodies (%) | 58 (77.3) | 9 (90.0) | 0.357 |
| SLEDAI (mean±SD) | 19±5 | 15±7 | 0.049 |
| Renal SLEDAI (mean±SD) | 11±2 | 8±4 | 0.014 |
| Non-renal SLEDAI (mean±SD) | 8±5 | 7±5 | 0.357 |
| mTOR inhibitors treatment | 0 | 0 | NA |
| Renal histopathology | |||
| Classification | 0.001 | ||
| Class II (%) | 0 (0.0) | 1 (10.0) | |
| Class III (%) | 9 (12.0) | 5 (50.0) | |
| Class IV (%) | 61 (81.3) | 2 (20.0) | |
| Class V (%) | 5 (6.7) | 2 (20.0) | |
| Activity index (median; IQR) | 8 (6–11) | 3 (2–7) | <0.001 |
| Activity index without endocapillary hypercellularity (median; IQR) | 7 (4–10) | 3 (1–7) | 0.001 |
| Cellular/Fibrocellular crescents (median; IQR) | 1 (0–2) | 0 (0–1) | 0.011 |
| Neutrophils/Karyorrhexis (median; IQR) | 1 (1–1) | 0 (0–0) | <0.001 |
| Fibrinoid necrosis (median; IQR) | 0 (0–0) | 0 (0–0) | 0.403 |
| Hyaline deposits (median; IQR) | 1 (0–1) | 0 (0–0) | <0.001 |
| Interstitial inflammation (median; IQR) | 1 (1–1) | 1 (1–1) | 0.154 |
| Chronicity index score (median; IQR) | 2 (1–4) | 1 (0–2) | 0.043 |
| Glomerulosclerosis score (median; IQR) | 0 (0–1) | 0 (0–1) | 0.777 |
| Fibrous crescents (median; IQR) | 0 (0–0) | 0 (0–0.25) | 0.853 |
| Tubular atrophy (median; IQR) | 1 (1–1) | 1 (0.75–1) | 0.144 |
| Interstitial fibrosis (median; IQR) | 1 (1–1) | 1 (1–1) | 0.335 |
Serum creatinine in mg/dL to mol/L, ×88.4.
dsDNA, double stranded DNA; LN, lupus nephritis; mTOR, mammalian target of the rapamycin; NA, not applicable; SLEDAI, SLE Disease Activity Index.